New chemical entity for optic neuritis and MS in development

[MSUK]

Bionure, Inc. a California-based late-preclinical drug development company, today announced that it has entered into a Sponsored Research Agreement with the US National Multiple Sclerosis Society through Fast Forward, its commercial research subsidiary aimed at accelerating the development of new and improved therapies for MS. Under this agreement, Fast Forward will provide funding to Bionure for the late-preclinical development of BN201 to enable IND filling to support the Phase 1 clinical study in Acute Optic Neuritis (AON). Optic neuritis is often a first sign of multiple sclerosis..... Read More - http://www.ms-uk.org/mssymptomsresearch